70794-13-7

Upstream product

• 56052-43-8 2-(2-Benzyloxyphenyl)ethanol 
• 40525-65-3 2-benzyloxyphenylacetic acid methyl ester 
• 22047-88-7 2-hydroxyphenylacetic acid benzyl ether 
• 637301-05-4 4-methoxybenzyl 2’-iodophenyl ether 
• 117637-79-3 ethyl 3-iodo-1H-indole-2-carboxylate 
• 533-58-4 2-Iodophenol 
• 3770-50-1 2-carbethoxyindole 
• 935846-39-2 2-(2-((4-methoxybenzyl)oxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 935846-44-9 ethyl 1-(tert-butoxycarbonyl)-3-[2-(4-methoxybenzyloxy)phenyl]-2-oxoindole-3-carboxylate 
• 935846-42-7 ethyl 3-[2-(4-methoxybenzyloxy)phenyl]-2-oxoindole-3-carboxylate 
• 935846-40-5 ethyl 3-[2-(4-methoxybenzyloxy)phenyl]indole-2-carboxylate 

Relevant academic research and scientific papers

Towards identifying potent new hits for glioblastoma

Glioblastoma is a devastating disease of the brain and is the most common malignant primary brain tumour in adults. The prognosis for patients is very poor with median time of survival after diagnosis measured in months, due in part to the tumours being highly aggressive and often resistant to chemotherapies. Alongside the ongoing research to identify key factors involved in tumour progression in glioblastoma, medicinal chemistry approaches must also be used in order to rapidly establish new and better treatments for brain tumour patients. Using a computational similarity search of the ZINC database, alongside traditional analogue design by medicinal chemistry intuition to improve the breadth of chemical space under consideration, six new hit compounds (14, 16, 18, 19, 20 and 22) were identified possessing low micromolar activity against both established cell lines (U87MG and U251MG) and patient-derived cell cultures (IN1472, IN1528 and IN1760). Each of these scaffolds provides a new platform for future development of a new therapy in this area, with particular promise shown against glioblastoma subtypes that are resistant to conventional chemotherapeutic agents.

Oxidative rearrangement of Indoles: A new approach to the EFHG-tetracyclic core of diazonamide A

(Chemical Equation Presented) A new approach to the ring EFHG-tetracyclic core fragment of the marine secondary metabolite diazonamide A is described. The route is based on the oxidative rearrangement of 3-arylindole-2-carboxylates. Thus, a range of 3-arylindole-2-carboxylates (3, 8) underwent rearrangement to the corresponding 3,3-disubstituted oxindoles (4, 9) with migration of the ester group upon treatment with tert-butyl hypochlorite followed by acid. The oxindoles 9 with a 3-[2-(4-methoxybenzyloxy)]phenyl substituent underwent cyclization to the tetracyclic aminals 11 following N-protection, reduction, and treatment with methanesulfonic anhydride. The methodology was applied to the tyrosine-indole derivative 17 to give the EFHG-tetracyclic core of diazonamide A.